Iovance Biotherapeutics: The High‑Risk Cancer Stock I Think Could Change a Portfolio by 2036

Core Viewpoint - Iovance Biotherapeutics has significant upside potential due to its innovative cancer treatment, Amtagvi, but it also faces considerable risks associated with clinical and regulatory challenges. Company Overview - Iovance Biotherapeutics is focused on developing Amtagvi, a cancer treatment derived from patients' own cells, which received approval for melanoma in early 2024 [4]. - The company reported a revenue of $263.5 million in fiscal year 2025, marking a 60.6% increase year over year, primarily driven by Amtagvi [4]. Product Development and Market Potential - Iovance is pursuing approvals for Amtagvi in multiple regions, including the European Union, the United Kingdom, Australia, and has already received approval in Canada [5]. - The company is also exploring label expansions for Amtagvi, with promising results from early-stage clinical trials for rare cancers [5]. - Amtagvi has received Fast Track Designation from the U.S. FDA for treating non-small cell lung cancer (NSCLC), which could expedite its development [6]. Future Outlook - The best-case scenario for Iovance involves launching Amtagvi in new markets, achieving label expansions, and maintaining consistent sales growth over the next decade [7]. - If Amtagvi captures a significant share of the NSCLC market, the company's stock could experience substantial growth driven by strong financial performance [7].